Investing Profile

Oscar Slotboom

InvestorVC
Managing Partner at BGV (BioGeneration Ventures)
Photo of Oscar Slotboom, Managing Partner at BGV (BioGeneration Ventures)

Signal uses Gmail to reveal intro paths. Email content is never read.

Sign in with Google →
Hotmail Network
4899 CONNECTIONS
Mckinsey & Company Network
309 CONNECTIONS
Mckinsey & Company Network
309 CONNECTIONS
Mckinsey & Company Network
309 CONNECTIONS
Mckinsey & Company Network
309 CONNECTIONS
cb
$100K - $1M
$500K
9
€250M
CompanyStageDateRound SizeTotal Raised
CatalYm
Series CNov 2022$52M
$200M
Co-investors: Colleen Cuffaro (Canaan Partners), Jon Edwards (Red Tree Venture Capital), Jonathan Tobin (Brandon Capital Partners), Nathalie Weitemeyer (Bayern Kapital), Rogier Rooswinkel (Hotmail), Marianne Uteng (Novartis Venture Fund)
NorthSea Therapeutics
Series CDec 2021$80M
Series BJan 2020$40M
Series ADec 2017$29M
$150M
Co-investors: Sander Slootweg (Forbion), Marco Boorsma (Forbion), Rob de Ree (Hotmail), Dirk Kersten (Forbion)
Dunad Therapeutics
Series ANov 2021$24M
$24M
VarmX
Series AJul 2018$9M
SeedJun 2017$1M
$83M
Co-investors: John de Koning (LSP), Roel Bulthuis (Syncona Limited), Hermann Hauser (Amadeus Capital Partners)
Mellon Medical
Series BAug 2017$7M
$7M
SurgVision
Series UnknownJan 2013
Co-investors: Rob de Ree (Hotmail)
Consultant Mckinsey & CompanyPresent
Fellow Mckinsey & CompanyPresent
Associate Mckinsey & CompanyPresent
Engagement Manager Mckinsey & CompanyPresent
Director Business Development CrucellPresent
Business Manager Paediatric CrucellPresent
BU Head, Vaccines and Infectious Diseases HotmailPresent
Chief Commercial Officer AvantiumPresent
Managing Partner BGV (BioGeneration Ventures)Present
Het Nieuwe Lyceum VWO General
Universiteit Twente MSE Chemical Engineering
University of Twente MSE Chemical Engineering
INSEAD MBA Business